Georgia-Pacific (GP) and Valmet have entered into a licensing agreement covering the tissue manufacturer’s eTAD(TM) technology.
Under the license agreement, Valmet will market, manufacture and install Advantage eTAD machines for tissue customers outside North America.
The technology was developed by GP and the company has three eTAD(TM) machines operating in North America, the latest two were re-built by Valmet in 2012.
The PM supplier said the eTAD concept provides “an ultra-premium product with high bulk to fibre ratio in combination with low energy and water consumption”.
Kurt Adams, vice president, R&D, GP, said: “We are pleased to license eTAD(TM) technology to Valmet as we recognise the value-creating potential of offering this technology more broadly.
“This technology meets consumer needs for premium qualities in tissue products, including softness and absorbency.”